Rabbit Polyclonal VEGFA antibody. Suitable for WB, IHC-P and reacts with Human samples. Cited in 22 publications. Immunogen corresponding to Synthetic Peptide within Human VEGFA aa 100-150.
Images
Publications
Filter by
- Genes 13:2022Ocular Manifestations in a Chinese Pedigree of Familial Amyloidotic Polyneuropathy Carrying the Transthyretin Mutation c.401A>G (p.Tyr134Cys)Applications:Unspecified applicationReactive species:Unspecified reactive speciesXiaonan Zhuang,Zhongcui Sun,Fengjuan Gao,Min Wang,Wenyi Tang,Wei Liu,Keyan Wang,Jihong Wu,Rui Jiang,Gezhi XuPubMed 35627273
- Bioengineering & translational medicine 7:e102552022Area light source-triggered latent angiogenic molecular mechanisms intensify therapeutic efficacy of adult stem cells.Applications:Unspecified applicationReactive species:Unspecified reactive speciesYu-Jin Kim,Sung-Won Kim,Gwang-Bum Im,Yeong Hwan Kim,Gun-Jae Jeong,Hye Ran Jeon,Dong-Ik Kim,Haeshin Lee,Sung Young Park,Sung Min Cho,Suk Ho BhangPubMed 35079630
- Frontiers in cell and developmental biology 9:7224272021An Adipose-Derived Injectable Sustained-Release Collagen Scaffold of Adipokines Prepared Through a Fast Mechanical Processing Technique for Preventing Skin Photoaging in Mice.Applications:Unspecified applicationReactive species:Unspecified reactive speciesXiaoxuan Jin,Yuchen Zhang,Xiangdong Zhang,Yibao Li,Mimi Xu,Kaiyang Liu,Jiangjiang Ru,Chijuan Ma,Yao Yao,Yunfan He,Jianhua GaoPubMed 34631708
- Oncology letters 22:7782021Dynamic contrast-enhanced MRI as a predictor of programmed death ligand-1 expression in patients with oral squamous cell carcinoma.Applications:Unspecified applicationReactive species:Unspecified reactive speciesNouha Tekiki,Mariko Fujita,Tatsuo Okui,Hotaka Kawai,May Wathone Oo,Toshiyuki Kawazu,Miki Hisatomi,Shunsuke Okada,Yohei Takeshita,Majd Barham,Hitoshi Nagatsuka,Yoshinobu Yanagi,Jun-Ichi AsaumiPubMed 34594419
- Experimental and therapeutic medicine 21:5962021Microcirculatory disturbance in acute liver injury.Applications:Unspecified applicationReactive species:Unspecified reactive speciesAkifumi Kuwano,Miho Kurokawa,Motoyuki Kohjima,Koji Imoto,Shigeki Tashiro,Hideo Suzuki,Masatake Tanaka,Seiji Okada,Masaki Kato,Yoshihiro OgawaPubMed 33884034
- Molecular therapy. Nucleic acids 24:1000-10112021miR-144 delivered by nasopharyngeal carcinoma-derived EVs stimulates angiogenesis through the FBXW7/HIF-1α/VEGF-A axis.Applications:Unspecified applicationReactive species:Unspecified reactive speciesXiaoyan Tian,Yuehui Liu,Zhi Wang,Shuhong WuPubMed 34094717
- Diabetologia 64:195-2102020Compromised barrier integrity of human feto-placental vessels from gestational diabetic pregnancies is related to downregulation of occludin expression.Applications:Unspecified applicationReactive species:Unspecified reactive speciesStephany Daniela Villota,Maria Toledo-Rodriguez,Lopa LeachPubMed 33001231
- Bioscience reports 40:2020Bioinformatics-based analysis of the lncRNA-miRNA-mRNA and TF regulatory networks reveals functional genes in esophageal squamous cell carcinoma.Applications:Unspecified applicationReactive species:Unspecified reactive speciesZhimin Ye,Jun Fang,Zhun Wang,Lei Wang,Bin Li,Tongxin Liu,Yuezhen Wang,Jianfeng Hua,FangZheng Wang,Zhenfu FuPubMed 32662828
- Communications biology 2:3862019Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake.Applications:Unspecified applicationReactive species:Unspecified reactive speciesSong Yi Ko et. al.PubMed 31646189
- Frontiers in oncology 9:3812019HypoxamiRs Profiling Identify miR-765 as a Regulator of the Early Stages of Vasculogenic Mimicry in SKOV3 Ovarian Cancer CellsApplications:Unspecified applicationReactive species:Unspecified reactive speciesYarely M Salinas-Vera et. al.PubMed 31157166
Key facts
- Isotype
- IgG
- Host species
- Rabbit
- Storage buffer
pH: 7.4
Preservative: 0.05% Sodium azide
Constituents: 50% Glycerol (glycerin, glycerine), 49% PBS- Form
- Liquid
- Clonality
- Polyclonal
Immunogen
- Synthetic Peptide within Human VEGFA aa 100-150. The exact immunogen used to generate this antibody is proprietary information. Database link P15692
Reactivity data
Select an application| WB | IHC-P | |
|---|---|---|
| Human | Tested | Tested |
WB
TestedTested
| Species | Dilution info | Notes |
|---|---|---|
Species Human | Dilution info 1/450.00000 - 1/2000.00000 | Notes - |
IHC-P
TestedTested
| Species | Dilution info | Notes |
|---|---|---|
Species Human | Dilution info 1/25.00000 - 1/100.00000 | Notes - |
Associated Products
Select an associated product type
7 products for Alternative Product
Target data
Function
N-VEGF. Participates in the induction of key genes involved in the response to hypoxia and in the induction of angiogenesis such as HIF1A (PubMed:35455969). Involved in protecting cells from hypoxia-mediated cell death (By similarity). VEGFA. Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth (PubMed:34530889). Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. Binds to the NRP1/neuropilin-1 receptor. Binding to NRP1 initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development (By similarity). Also binds the DEAR/FBXW7-AS1 receptor (PubMed:17446437). Isoform VEGF165B. Binds to the KDR receptor but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.
Alternative names
VEGF, VEGFA, L-VEGF, Vascular permeability factor, VPF
Recommended products
Rabbit Polyclonal VEGFA antibody. Suitable for WB, IHC-P and reacts with Human samples. Cited in 22 publications. Immunogen corresponding to Synthetic Peptide within Human VEGFA aa 100-150.
Key facts
- Isotype
- IgG
- Host species
- Rabbit
- Storage buffer
pH: 7.4
Preservative: 0.05% Sodium azide
Constituents: 50% Glycerol (glycerin, glycerine), 49% PBS- Form
- Liquid
- Clonality
- Polyclonal
- Immunogen
- Synthetic Peptide within Human VEGFA aa 100-150. The exact immunogen used to generate this antibody is proprietary information. Database link P15692
- Purification technique
- Affinity purification Immunogen
- Concentration
Storage
- Shipped at conditions
- Blue Ice
- Appropriate short-term storage duration
- 1-2 weeks
- Appropriate short-term storage conditions
- +4°C
- Appropriate long-term storage conditions
- -20°C
- Aliquoting information
- Upon delivery aliquot
- Storage information
- Avoid freeze / thaw cycle
Notes
Abcam is leading the way to address reproducibility in scientific research with our highly validated recombinant monoclonal and recombinant multiclonal antibodies. Search & select one of Abcam's thousands of recombinant alternatives to eliminate batch-variability and unnecessary animal use.
If you do not find a host species to meet your needs, our catalogue and custom Chimeric range provides scientists the specificity of Abcam's RabMAbs in the species backbone of your choice. Remember to also review our range of edited cell lines, proteins and biochemicals relevant to your target that may help you further your research goals.
Abcam antibodies are extensively validated in a wide range of species and applications, so please check the reagent specifications meet your scientific needs before purchasing. If you have any questions or bespoke requirements, simply visit the Contact Us page to send us an inquiry or contact our Support Team ahead of purchase.
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
Vascular endothelial growth factor A (VEGFA) also known as VEGF or vascular permeability factor (VPF) is a protein that plays a central role in angiogenesis as well as in the growth of blood vessels. The molecular weight of VEGFA varies depending on the isoform typically ranging from 34 to 42 kDa. VEGFA is expressed in many tissues including fibroblasts macrophages endothelial cells and platelets. Its expression levels can increase in response to stimuli like hypoxia or inflammatory cytokines. VEGFA is an important target in research for therapies related to vascular diseases and cancer.
- Biological function summary
VEGFA functions by promoting the proliferation and migration of vascular endothelial cells. It operates both as a homodimer and as part of complex signaling cascades interacting with VEGF receptors on cell surfaces to trigger downstream signals for angiogenesis. This includes endothelial cell growth migration and the new blood vessel formation process. VEGFA's activity is important for physiological processes such as wound healing and embryonic development and it also contributes to pathological conditions through its unregulated expression in diseases.
- Pathways
Many processes involve VEGFA including the PI3K/AKT pathway and the MAPK/ERK pathway. These pathways regulate cell survival growth and differentiation. Other proteins like PLGF (placenta growth factor) and VEGFB often accompany VEGFA in these pathways aiding in distinct but overlapping roles. These interactions are transmitted through binding to VEGF receptors such as VEGFR-1 and VEGFR-2 subsequently activating various signaling cascades necessary for cellular and tissue homeostasis.
- Associated diseases and disorders
VEGFA relates to cancer and age-related macular degeneration among others. In cancer overexpression of VEGFA can lead to excessive angiogenesis supplying blood to tumors and facilitating tumor growth. In age-related macular degeneration upregulation of VEGFA contributes to the progression of the disease by promoting the formation of abnormal blood vessels under the retina. Anti-VEGFA therapies such as anti-VEGF antibodies (e.g. bevacizumab) can target these overexpressed pathways. VEGFA interacts with other proteins like HIF-1α which regulates its expression under hypoxia a common condition in tumors.
Product promise
Tested
We have tested this species and application combination and it works. It is covered by our product promise.
Expected
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
Predicted
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
Not recommended
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
4 product images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGFA antibody (ab183100)
Immunohistochemical analysis of paraffin embedded Human liver cancer tissue labeling VEGFA with ab183100 at 1/25 dilution. Image on the right is treated with the synthetic peptide.
Western blot - Anti-VEGFA antibody (ab183100)
All lanes: Western blot - Anti-VEGFA antibody (ab183100) at 1/450 dilution
Lane 1: Hela cell lysate at 40 µg
Lane 2: Jurkat cell lysate at 40 µg
Lane 3: 293T cell lysate at 40 µg
Lane 4: 231 cell lysate at 40 µg
SecondaryAll lanes: Goat anti Rabbit IgG - H&L (HRP) at 1/10000 dilution
Predicted band size: 27 kDa
Exposure time: 2min
Western blot - Anti-VEGFA antibody (ab183100)
All lanes: Western blot - Anti-VEGFA antibody (ab183100) at 1/1000 dilution
Lane 1: HeLa (human epithelial cell line from cervix adenocarcinoma) cell lysate at 30 µg
Lane 2: HEK-293T (human epithelial cell line from embryonic kidney transformed with large T antigen) cell lysate at 30 µg
Lane 3: HepG2 (human liver hepatocellular carcinoma cell line) cell lysate at 30 µg
Lane 4: HT29 cell lysate at 30 µg
Lane 5: MDA-MB-231 (human breast adenocarcinoma cell line) cell lysate at 30 µg
Lane 6: A549 (human lung carcinoma cell line) cell lysate at 30 µg
Lane 7: SK-OV-3 (human ovarian cancer cell line) cell lysate at 30 µg
SecondaryAll lanes: Goat anti Rabbit IgG - H&L (HRP) at 1/100 dilution
Developed using the ECL technique.
Predicted band size: 27 kDa
Exposure time: 2min
Image collected and cropped by CiteAb under a CC-BY license from the publication
Western blot - Anti-VEGFA antibody (ab183100)
VEGFA western blot using anti-VEGFA antibody ab183100. Publication image and figure legend from Wei, X., Zhang, K., et al., 2018, BMC Cancer, PubMed 29843634.
ab183100 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab183100 please see the product overview.
Widespread changes of gene expressions and critical pathways in human lung adenocarcinoma cells A549 with GMDS knockdown. a Heatmap containing 739 differentially expressed genes in human lung adenocarcinoma cell line A549 infected with lentivirus expressing either Scr-shRNA (purple) or GMDS-shRNA (red) with the criteria P < 0.05 and ▏fold change ▏ > 1.5. Genes and samples were listed in rows and columns, respectively. A colour standard for normalized expression data was shown at the bottom of the microarray heatmap (green represents downregulated genes while red represents upregulated genes). b Gene expression changes identified in microarray were confirmed using real-time quantitative PCR for selected genes CASP8, MAP3K7, CDKN1A, FAS, JUN, DDIT3, VEGFA, SKA1 and MAD2L1 in human lung adenocarcinoma cell line A549 infected with lentivirus expressing either Scr-shRNA or GMDS-shRNA. Histogram shown here was one out of three independent experiments (p < 0.01) and normalized to GAPDH. c Protein level of FAS, VEGFA, DDIT3, JUN and CDKN1A in human human lung adenocarcinoma cell line A549 infected with lentivirus expressing either Scr-shRNA or GMDS-shRNA. GAPDH was used as internal control. d Caspase3/7 activity analysis in A549 cells and H1299 cells infected with lentivirus expressing either Scr-shRNA or GMDS-shRNA. Data shown are the mean ± SEM of caspase3/7 activity from three independent experiments (**, p < 0.01)
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com